Key result
In a cohort of 131 patients with transverse myelitis, 36.6% achieved full recovery while 63.4% had poor recovery with significant neurological deficits at eight weeks follow-up.
Why the study?
While some patients recover from transverse myelitis with minor or no residual issues, others suffer permanent impairments affecting daily living, prompting an assessment of clinical outcome frequencies.
Cohort (n=131)
No
In a Pakistani cohort of patients with transverse myelitis, 63.4% experienced poor recovery with significant neurological deficits at 8 weeks, highlighting the high morbidity associated with the disease.
BACKGROUND: Transverse myelitis (TM) is an inflammatory disorder of spinal cord, characterized by acute or sub-acute dysfunction of spinal cord affecting the motor, sensory, and autonomic systems. It may be idiopathic or related to other diseases. Although some patients recover from TM with minor or no residual problems, others suffer permanent impairments that affect their ability to perform ordinary tasks of daily living. Our objective was to determine the frequency of different clinical outcomes in patients presenting with TM. METHODS: It was a prospective cohort clinical study conducted from May 2018 till October 2018. Study was conducted in the Department of Neurology at Jinnah Medical College Hospital (JMCH), Karachi. In total 131 patients of TM were enrolled and treated as per standard protocol, and re-evaluated after eight weeks for assessment of clinical outcomes. RESULTS: The average age of patients was 51.15 ± 6.56 years. Out of 131 cases, 36.6% of patients had full recovery and 63.4% had poor recovery while recurrence occurred in 66.7% cases. Urinary frequency was observed in 12.2% cases and incontinence in 6.9% cases. CONCLUSION: Acute TM has become transformed with recent developments, especially the advent of the MRI and the discovery of biomarkers.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2019) conducted a cohort in Transverse Myelitis (n=131). Standard protocol was evaluated on Full recovery at 8 weeks. In a cohort of 131 patients with transverse myelitis, 36.6% achieved full recovery while 63.4% had poor recovery with significant neurological deficits at eight weeks follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: